Free Trial
NASDAQ:GMAB

Genmab A/S (GMAB) Stock Price, News & Analysis

Genmab A/S logo
$24.87 -0.24 (-0.96%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$24.88 +0.00 (+0.02%)
As of 08/29/2025 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Genmab A/S Stock (NASDAQ:GMAB)

Key Stats

Today's Range
$24.75
$25.00
50-Day Range
$20.41
$25.11
52-Week Range
$17.24
$27.93
Volume
676,680 shs
Average Volume
1.34 million shs
Market Capitalization
$15.96 billion
P/E Ratio
12.50
Dividend Yield
N/A
Price Target
$37.60
Consensus Rating
Moderate Buy

Company Overview

Genmab A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

GMAB MarketRank™: 

Genmab A/S scored higher than 72% of companies evaluated by MarketBeat, and ranked 287th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Genmab A/S has only been the subject of 3 research reports in the past 90 days.

  • Read more about Genmab A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Genmab A/S are expected to grow by 22.76% in the coming year, from $1.45 to $1.78 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genmab A/S is 12.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 268.93.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genmab A/S is 12.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.11.

  • Price to Earnings Growth Ratio

    Genmab A/S has a PEG Ratio of 7.29. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Genmab A/S has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Genmab A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.58% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genmab A/S has recently decreased by 1.91%, indicating that investor sentiment is improving.
  • Dividend Yield

    Genmab A/S does not currently pay a dividend.

  • Dividend Growth

    Genmab A/S does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.58% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genmab A/S has recently decreased by 1.91%, indicating that investor sentiment is improving.
  • News Sentiment

    Genmab A/S has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Genmab A/S this week, compared to 7 articles on an average week.
  • Search Interest

    Only 11 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genmab A/S insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.54% of the stock of Genmab A/S is held by insiders.

  • Percentage Held by Institutions

    Only 7.07% of the stock of Genmab A/S is held by institutions.

  • Read more about Genmab A/S's insider trading history.
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GMAB Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.tc pixel
William Blair Remains Bullish on Genmab A/S (GMAB)
See More Headlines

GMAB Stock Analysis - Frequently Asked Questions

Genmab A/S's stock was trading at $20.87 on January 1st, 2025. Since then, GMAB stock has increased by 19.2% and is now trading at $24.87.

Genmab A/S Sponsored ADR (NASDAQ:GMAB) posted its quarterly earnings results on Thursday, August, 7th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.15. The company had revenue of $925 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a net margin of 37.53% and a trailing twelve-month return on equity of 21.03%.
Read the conference call transcript
.

Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Genmab A/S's top institutional shareholders include Alliancebernstein L.P. (1.66%), Orbis Allan Gray Ltd (1.23%), Arrowstreet Capital Limited Partnership (0.54%) and Marshall Wace LLP (0.30%).

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Meta Platforms (META), Tesla (TSLA) and Datadog (DDOG).

Company Calendar

Last Earnings
8/07/2025
Today
8/30/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GMAB
CIK
1434265
Fax
N/A
Employees
1,660
Year Founded
1999

Price Target and Rating

High Price Target
$48.00
Low Price Target
$27.00
Potential Upside/Downside
+51.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.99
Trailing P/E Ratio
12.50
Forward P/E Ratio
17.15
P/E Growth
7.29
Net Income
$1.14 billion
Net Margins
37.53%
Pretax Margin
42.63%
Return on Equity
21.03%
Return on Assets
16.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.22
Quick Ratio
6.20

Sales & Book Value

Annual Sales
$3.12 billion
Price / Sales
5.11
Cash Flow
$1.50 per share
Price / Cash Flow
16.56
Book Value
$8.26 per share
Price / Book
3.01

Miscellaneous

Outstanding Shares
641,540,000
Free Float
631,663,000
Market Cap
$15.96 billion
Optionable
Optionable
Beta
0.95

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:GMAB) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners